Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2015 - 2026)

Insight Molecular Diagnostics has reported Cash & Current Investments for 12 years, with the latest figure at $28.9 million in Q1 2026.

• Quarterly Cash & Current Investments fell 6.68% year-over-year to $28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.9 million (down 6.68% YoY) and the FY2025 annual result came in at $12.3 million, up 42.57% from the prior year.
• Cash & Current Investments grew to $28.9 million in Q1 2026 per IMDX's latest filing, from $12.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $45.4 million in Q2 2022 and troughed at $866000.0 in Q4 2022.
• A 5-year average of $17.4 million and a median of $14.2 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments surged 989.15% in 2023, then slumped 76.13% in 2024.
• Over 5 years, Cash & Current Investments stood at $866000.0 in 2022, then soared by 989.15% to $9.4 million in 2023, then slipped by 8.44% to $8.6 million in 2024, then surged by 42.57% to $12.3 million in 2025, then soared by 134.97% to $28.9 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $28.9 million, $12.3 million, and $19.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.